Pharma Journalist -

Seattle Genetics, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and…
Read More...

Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel…
Read More...

The Phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating…
Read More...

London – On Wednesday, 27th May, OCT Virtual (https://arena-international.com/octvirtual/) will delve into challenges the clinical trials community is facing as the disruption from…
Read More...

Ocular Therapeutix, Inc. announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye…
Read More...

Bellerophon Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application, allowing the Company to initiate a…
Read More...

Themis, a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and ABL Europe (ABL), a global Contract Development and…
Read More...

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation…
Read More...

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment…
Read More...

Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, announced the company’s launch from stealth mode with its proprietary platform,…
Read More...